Artal Group S.A. increased its holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 1.3% in the fourth quarter, HoldingsChannel.com reports. The fund owned 58,274,650 shares of the biopharmaceutical company’s stock after purchasing an additional 756,673 shares during the quarter. Lexicon Pharmaceuticals accounts for approximately 8.7% of Artal Group S.A.’s portfolio, making the stock its 3rd largest position. Artal Group S.A. owned 0.55% of Lexicon Pharmaceuticals worth $575,754,000 at the end of the most recent quarter.
A number of other large investors have also added to or reduced their stakes in LXRX. Kornitzer Capital Management Inc. KS purchased a new stake in Lexicon Pharmaceuticals in the third quarter worth about $9,420,000. State Street Corp lifted its stake in Lexicon Pharmaceuticals by 19.9% in the second quarter. State Street Corp now owns 1,967,255 shares of the biopharmaceutical company’s stock worth $32,363,000 after acquiring an additional 326,088 shares during the period. Pinnacle Associates Ltd. lifted its stake in Lexicon Pharmaceuticals by 25.5% in the third quarter. Pinnacle Associates Ltd. now owns 897,045 shares of the biopharmaceutical company’s stock worth $11,025,000 after acquiring an additional 182,215 shares during the period. Tocqueville Asset Management L.P. purchased a new stake in Lexicon Pharmaceuticals in the third quarter worth about $1,659,000. Finally, Sector Gamma AS lifted its stake in Lexicon Pharmaceuticals by 18.4% in the third quarter. Sector Gamma AS now owns 737,453 shares of the biopharmaceutical company’s stock worth $9,063,000 after acquiring an additional 114,798 shares during the period.
A number of analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, January 31st. BidaskClub raised shares of Lexicon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, January 20th. ValuEngine lowered shares of Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. JPMorgan Chase & Co. lowered shares of Lexicon Pharmaceuticals from a “neutral” rating to an “underweight” rating and lowered their price objective for the stock from $15.00 to $10.00 in a research note on Wednesday. Finally, Wedbush reaffirmed an “outperform” rating and issued a $38.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Thursday, November 30th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. Lexicon Pharmaceuticals presently has an average rating of “Hold” and an average target price of $24.80.
Shares of Lexicon Pharmaceuticals, Inc. (LXRX) opened at $7.86 on Friday. The company has a market cap of $822.59, a PE ratio of -6.19 and a beta of 0.24. Lexicon Pharmaceuticals, Inc. has a 1 year low of $7.80 and a 1 year high of $18.00. The company has a current ratio of 1.66, a quick ratio of 1.65 and a debt-to-equity ratio of 1.09.
COPYRIGHT VIOLATION NOTICE: “Artal Group S.A. Has $575.75 Million Position in Lexicon Pharmaceuticals, Inc. (LXRX)” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/18/artal-group-s-a-has-575-75-million-position-in-lexicon-pharmaceuticals-inc-lxrx.html.
Lexicon Pharmaceuticals Profile
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
Want to see what other hedge funds are holding LXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX).
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.